Schott is building a second melting tank for pharmaceutical glass tubing at its main plant in Mainz, Germany, a $49m investment. The production facility is scheduled to go into operation in mid-2022 and will offer 100 jobs, 50 of which will be directly at Schott.
"We decided in favor of the Mainz site in order to further strengthen our production base for pharmaceutical glass tubing in Germany and Europe. In doing so, we naturally also have our sights set on the manufacturers of COVID-19 pandemic vaccines based here and the European pharmaceutical industry as a whole," said Dr Frank Heinricht, Chairman of the Board of Management of Schott.
Schott is also exploring possible support with subsidies in talks with the regional government of Rhineland-Palatinate, the federal government of Germany and the European Union.
The pharmaceutical glass production in Mainz is part of a global production network of the company’s tubing business unit, which also includes the Mitterteich site in Germany as well as factories in Brazil, India and China. Schott significantly expanded its production capacities for pharmaceutical tubing in Asia in 2020 with the commissioning of another tank in India and a plant in China.
